Hence, STAT3 activation is crucial for inducing PD-L1 expression in tumor cells and inhibition of STAT3 activity may inhibit the CXCL9/CXCR3 signaling-induced PD-L1 expression, benefiting bladder cancer patients. This evidence concerns the gene CXCL9 and urinary bladder cancer.